1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsPainW. I. S.
E. Grant is sponsored by Pain Alliance Europe (sponsored by Grünenthal). This grant focuses on empowering individuals to manage chronic pain effectively through education, support, and self-care initiatives.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Grünenthal supported pain-related projects and initiatives | Grünenthal You are now leaving the Grünenthal website. You will be re-directed to an external website. Grünenthal accepts no responsibility for the content of other websites.
Increasing access and awareness Patients and their families need support with managing pain and its consequences. Grünenthal is actively involved in several impact-driven initiatives that help pain patients get back to normal living quickly and sustainably. We are proud to share these selected highlight projects.
Grünenthal established Change Pain in 2009 with the aim of creating a better understanding of pain patients’ needs and developing solutions that improve pain management. It was launched in 12 European countries, and is endorsed by the European Pain Federation EFIC® and Pain Alliance Europe (PAE).
Since it was launched, Change Pain has supported the development of a wide range of tools that make physicians’ daily practice easier. More than 65,000 healthcare professionals have been involved in its educational activities via in-person workshops and web-based learning modules.
EFIC-Grünenthal-Grant (E-G-G) This initiative supports early-career scientists in carrying out innovative clinical research into pain within countries that are members of the European Pain Federation EFIC®. Grünenthal provides up to €110,000 of funding for this grant each year. Individual research grants worth a maximum of €50,000 are available for projects with a duration of up to two years.
These grants target clinical and human experimental pain research, including innovative educational initiatives that improve pain diagnosis and treatment. Grants are allocated by a sub-group of the EFIC® Working Group for Grants and Prizes. Societal Impact of Pain (SIP) The SIP platform is a multi-stakeholder partnership that aims to raise awareness of pain and change pain policies.
It is led by the European Pain Federation EFIC® and Pain Alliance Europe (PAE). Grünenthal and Pfizer are its main sponsors. SIP provides opportunities for discussion among stakeholders including healthcare professionals, pain advocacy groups, politicians, healthcare insurance providers, representatives from health authorities, regulators, and budget holders.
It is endorsed by more than 310 European patient and healthcare authorities, and collaborates with a range of organisations to advocate for improved pain management. In May 2025, Pain Alliance Europe introduced the PainW. I.
S. E (Pain, Wellbeing, Innovation, Self-management, Empowerment) Grant, which is sponsored by Grünenthal. This initiative aims to empower people living with chronic pain through education, support, and self-care, evolving from the previous Brain Mind and Pain (BMP) Grant.
The grant strives to foster initiatives driven by patients and patient organizations or in collaboration with them, focusing on raising awareness of the challenges faced by those with chronic pain and improving their quality of life through better management and prevention. PainW. I.
S. E. Grant - Pain Alliance Europe E-G-G winner Jonas Zaman 2024 is the twentieth anniversary of the EFIC-Grünenthal-Grant (E-G-G) for pain research.
Previous winner Jonas Zaman describes how this unique funding programme impacted his life – and enabled further successes in his career as a pain scientist. E-G-G winner Joukje Oosterman The EFIC-Grünenthal-Grant has now funded pain research for 20 years. Joukje Oosterman won this prestigious grant in 2017 – and it enabled her to investigate fresh areas of research that are still helping to advance her career in pain science.
Winning pain research projects 2025 Chronic pain affects 20 percent of people worldwide. 1 The EFIC-Grünenthal-Grant (E-G-G) aims to improve quality of life for those patients by supporting innovative pain research – and is now announcing its three winning projects for 2025!
Winning pain scientists 2023 Three early-career scientists in Europe are now conducting pioneering research into chronic pain – after winning the prestigious EFIC-Grünenthal-Grant. Who are these young innovators and what are they investigating?
Nearly 20 years of pain research funding For nearly 20 years, the European Pain Federation EFIC and Grünenthal have supported innovative projects in human pain research by early-career scientists and physicians from any member country of the EFIC through the biennial EFIC ® -Grünenthal-Grant (E-G-G). EFIC ® -Grünenthal-Grant (received 79 applications.
In a two-step evaluation, seven selected reviewers and four members of the EFIC ® Research Committee Working Group on Grants and Prizes selected 5 research projects for funding. Get to know the winners.
According to the current listing, eligibility includes: Collaborations with patients and patient organizations are central. Projects should aim to improve the quality of life for people with chronic pain. Confirm the full requirements in the official notice before applying.
PainW.I.S.E. Grant is funded by Pain Alliance Europe (sponsored by Grünenthal). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
The HEAL Initiative's Studies to Enable Analgesic Discovery award (RFA-NS-25-023) puts federal money exactly where private capital won't go — the assay-building, screening, and hit-characterization stage of non-opioid pain therapeutics. It's a phased R61/R33, up to $350,000 in direct costs per year, with the next application deadline September 17, 2026. Here is how the two-phase structure works, who's eligible, and how to build a proposal that survives the R61-to-R33 milestone gate.
Read articleThe EU's last major Horizon Europe work programme puts €14B on the table through 2027. A strategic breakdown of budgets, deadlines, eligibility, and how US-based teams can compete.
Read articleThe EU committed €900 million to lure researchers with relocation grants worth up to €2 million each. France placed 41 of 46 recruits from the US. Here is what the global talent war means for American research institutions and grant seekers.
Read article